Lvw Advisors, LLC Abb Vie Inc. Transaction History

Lvw Advisors, LLC

$771 Million
Q3 2024

A detailed history of Lvw Advisors, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Lvw Advisors, LLC holds 23,252 shares of ABBV stock, worth $4.19 Million. This represents 0.6% of its overall portfolio holdings.

Number of Shares

23,252

Previous 24,160 3.76%

Holding current value

$4.19 Million

Previous $4.14 Million 10.81%

% of portfolio

0.6%

Previous 0.61%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 09, 2024	SELL	$163.84 - $199.33 $148,766 - $180,991	-908 Reduced 3.76%	23,252 $4.59 Million
Q2 2024 Jul 15, 2024	SELL	$154.79 - $180.76 $106,340 - $124,182	-687 Reduced 2.76%	24,160 $4.14 Million
Q1 2024 Apr 17, 2024	SELL	$159.82 - $182.1 $303,178 - $345,443	-1,897 Reduced 7.09%	24,847 $4.52 Million
Q4 2023 Jan 12, 2024	SELL	$137.6 - $154.97 $393,398 - $443,059	-2,859 Reduced 9.66%	26,744 $4.14 Million
Q3 2023 Oct 10, 2023	SELL	$133.59 - $154.65 $479,588 - $555,193	-3,590 Reduced 10.82%	29,603 $4.41 Million
Q2 2023 Jul 14, 2023	SELL	$132.51 - $164.9 $320,806 - $399,222	-2,421 Reduced 6.8%	33,193 $4.47 Million
Q1 2023 May 02, 2023	SELL	$144.61 - $166.54 $267,673 - $308,265	-1,851 Reduced 4.94%	35,614 $5.68 Million
Q4 2022 Jan 18, 2023	SELL	$138.31 - $165.87 $208,294 - $249,800	-1,506 Reduced 3.86%	37,465 $0
Q3 2022 Oct 13, 2022	BUY	$134.21 - $153.93 $3,489 - $4,002	26 Added 0.07%	38,971 $5.23 Million
Q2 2022 Jul 22, 2022	SELL	$137.62 - $174.96 $668,145 - $849,430	-4,855 Reduced 11.08%	38,945 $5.97 Million
Q1 2022 May 02, 2022	SELL	$131.98 - $163.75 $206,020 - $255,613	-1,561 Reduced 3.44%	43,800 $7.1 Million
Q4 2021 Jan 26, 2022	SELL	$107.43 - $135.93 $441,107 - $558,128	-4,106 Reduced 8.3%	45,361 $6.14 Million
Q3 2021 Nov 02, 2021	BUY	$106.4 - $120.78 $44,049 - $50,002	414 Added 0.84%	49,467 $5.34 Million
Q2 2021 Jul 15, 2021	BUY	$105.21 - $117.21 $61,442 - $68,450	584 Added 1.2%	49,053 $5.53 Million
Q1 2021 Apr 19, 2021	SELL	$102.3 - $112.62 $61,891 - $68,135	-605 Reduced 1.23%	48,469 $5.25 Million
Q4 2020 Feb 04, 2021	SELL	$80.49 - $108.67 $3,541 - $4,781	-44 Reduced 0.09%	49,074 $5.26 Million
Q3 2020 Oct 29, 2020	SELL	$85.91 - $100.83 $212,884 - $249,856	-2,478 Reduced 4.8%	49,118 $4.3 Million
Q2 2020 Aug 11, 2020	SELL	$73.37 - $98.18 $660 - $883	-9 Reduced 0.02%	51,596 $5.07 Million
Q1 2020 Apr 23, 2020	BUY	$64.5 - $97.79 $80,625 - $122,237	1,250 Added 2.48%	51,605 $3.93 Million
Q4 2019 Feb 10, 2020	SELL	$72.13 - $90.25 $26,543 - $33,212	-368 Reduced 0.73%	50,355 $4.46 Million
Q3 2019 Oct 22, 2019	BUY	$62.98 - $75.72 $737,621 - $886,832	11,712 Added 30.02%	50,723 $3.84 Million
Q2 2019 Aug 14, 2019	BUY	$65.7 - $83.98 $316,476 - $404,531	4,817 Added 14.09%	39,011 $2.84 Million
Q1 2019 May 03, 2019	SELL	$77.14 - $90.79 $38,415 - $45,213	-498 Reduced 1.44%	34,194 $2.76 Million
Q4 2018 Feb 05, 2019	BUY	$77.85 - $96.01 $286,410 - $353,220	3,679 Added 11.86%	34,692 $3.2 Million
Q3 2018 Nov 02, 2018	BUY	$88.91 - $98.84 $47,300 - $52,582	532 Added 1.75%	31,013 $2.93 Million
Q2 2018 Jul 31, 2018	BUY	$89.78 - $106.23 $14,095 - $16,678	157 Added 0.52%	30,481 $2.82 Million
Q1 2018 Apr 20, 2018	SELL	$92.01 - $123.21 $388,190 - $519,822	-4,219 Reduced 12.21%	30,324 $2.87 Million
Q4 2017 Feb 12, 2018	SELL	$89.56 - $98.21 $299,309 - $328,217	-3,342 Reduced 8.82%	34,543 $3.34 Million
Q3 2017 Nov 09, 2017	SELL	$69.85 - $89.22 $96,602 - $123,391	-1,383 Reduced 3.52%	37,885 $3.37 Million
Q2 2017 Aug 10, 2017	BUY	N/A	39,268	39,268 $2.85 Million

Others Institutions Holding ABBV

# of Institutions

3,853

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lvw Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lvw Advisors, LLC with notifications on news.

Account